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Abstract
SHIVsbg, expressing Vpu, Tat, Rev, and Env proteins of HIV-1 Lai, was shown to be infectious for rhesus macaques. In this study, we
mutated SHIVsbg Nef amino acids 17–18 from RQ to YE, conferring to SHIVsbg-YE the ability to replicate in vitro in unstimulated
macaque PBMC. Juvenile macaques inoculated intravenously or orally with SHIVsbg-YE developed persistent infection. All macaques lost
weight during the first 17 weeks but recovered afterward. All animals developed a strong HIV-specific humoral immune response. Viruses
isolated 2 years postinoculation lost the ability to replicate in unstimulated macaque PBMC. Point mutations or 33-bp-wide deletions in the
nef ITAM motif were responsible for this phenotype and correlated with clinical improvement of the infected macaques. These data
demonstrate that the ITAM domain is inactivated in animals developing an acute antiviral immune response and may be detrimental to viral
replication, perhaps by interfering with other well-conserved functions of SIV Nef protein.
© 2003 Elsevier Science (USA). All rights reserved.
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Introduction
Since the isolation of human immunodeficiency virus
type 1 (HIV-1) and HIV-2 (Barre- Sinoussi et al., 1983;
Clavel et al., 1986), progress has been made in the under-
standing of in vivo viral dynamics (Chun et al., 1997; Ho et
al., 1995; Mellors et al., 1996; Wei et al., 1995), but further
comprehension of HIV-induced pathology and development
of a vaccine require the use of an animal model. As HIV-1
does not induce disease in experimentally infected nonhu-
man primates, infection of macaques with simian immuno-
deficiency virus (SIV) has been used as surrogate to study
pathogenesis induced by primate lentiviruses (Kestler et al.,
1990). However this model has limited utility for develop-
ing a vaccine based on induction of an envelope-specific
immune response due to the differences between HIV and
SIV envelope glycoproteins (Burns and Desrosiers, 1991;
Javaherian et al., 1992; Overbaugh et al., 1991).
To overcome this problem, chimeric simian–human im-
munodeficiency viruses (SHIV) have been constructed by
replacing tat, rev, and env genes of the pathogenic SIV-
mac239 molecular clone by tat, rev, vpu, and env genes of
HIV-1 strains (Bogers et al., 1997; Igarashi et al., 1994;
Kuwata et al., 1996; Li et al., 1992, 1995; Luciw et al.,
1995; Reimann et al., 1996a; Sakuragi et al., 1992; Shibata
et al., 1991, 1997). We previously described the infection of
rhesus and cynomolgus macaques with SHIVsbg, a virus
carrying tat, rev, vpu, and env genes of HIV-1 Lai (Dunn et
al., 1996). Although SHIVsbg replicated to high levels in
macaques during primary infection and caused CD4 lym-
phocyte depletion, macaques remained asymptomatic for
years and few animals developed simian AIDS (Dunn et al.,
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1996; and our unpublished data). Several groups have ob-
tained SHIVs with increased virulence after serial passages
in macaques (Joag et al., 1996; Reimann et al., 1996b;
Stephens et al., 1996). This process of adaptation results in
multiple mutations and the emergence of viruses with in-
creased replication capacity in macaques (Cayabyab et al.,
1999; Harouse et al., 1999; Igarashi et al., 1996; Karlsson et
al., 1997). Introduction of specific sequences from patho-
genic SIV strains is another approach. For example,
SIVsmmPBj14 is a highly virulent strain, which naturally
evolved in a pig-tailed macaque (Macaca nemestrina) in-
fected with SIVsmm9 (Fultz et al., 1989; Tao and Fultz,
1995). The viral strain, recovered 14 months after inocula-
tion, was extremely pathogenic for pig-tailed macaques.
Indeed, intravenously infected monkeys developed acute
disease (diarrhea, anorexia, depression, and rash) and died
within 1 or 2 weeks postinoculation. SIVsmmPBj14 repli-
cated to a high level and induced extensive hyperplasia of T
-cell zones, especially in the gut-associated lymphoid tis-
sues (Fultz, 1994). The in vivo phenotype of SIVsmmPBj14
was associated with the ability of the virus to replicate in
vitro in unstimulated macaque peripheral blood mononu-
clear cells (PBMC) and to induce cell proliferation (Fultz,
1991; Fultz and Zack, 1994). Using molecular clones hav-
ing varying pathogenicity, Novembre et al. demonstrated
that multiple genes are involved in SIVsmmPBj14 acute
virulence but deletion of nef gene abrogated the lethal phe-
notype in macaques, indicating a major contribution of this
gene product (Novembre et al., 1993, 1996). Furthermore
the SIVsmmPBj14 nef gene has a sequence variant YE at
amino acids 17–18 that creates an immunoreceptor tyrosine
base motif (ITAM, TyrX2Leu/IleX7TyrX2Leu/Ile, where X
is any amino acid). Conversion of sequence of SIVmac239
nef gene at these positions from RQ to YE conferred the
mutated virus the capacity to replicate in resting PBMC in
vitro and induces the SIVsmmPBj14 phenotype in vivo (Du
et al., 1995, 1996; Sasseville et al., 1996).
In this study, we introduced the YE sequence variant into
SHIVsbg nef gene. This molecular clone is an X4 virus and
therefore its cell tropism differs from that of YE virus
mutants generated earlier as SIVmac239 uses CCR5 as
coreceptor while SHIVMD14YE has an envelope derived
from a dual tropic HIV-1 isolate (Du et al., 1995; Shibata et
al., 1997). Nevertheless, the mutation RQ to YE conferred
to SHIVsbg the ability to replicate in unstimulated macaque
PBMC. Juvenile macaques inoculated intravenously and
orally with SHIVsbg-YE developed persistent infection and
lost weight during the first 17 weeks. However they did not
manifest other symptoms of acute SIVsmmPBj14 infection.
Viruses isolated 2 years postinoculation did conserve the
CXCR4 coreceptor usage as the inoculated virus but had
lost the ability to replicate in unstimulated macaque PBMC.
Different alterations in the nef gene ITAM motif were
responsible for this phenotype. This data demonstrate that
ITAM domain is inactivated in animals developing an acute
antiviral immune response and may be detrimental to viral
replication, perhaps by interfering with other well-con-
served function of SIV Nef protein.
Results
In vitro characterization of SHIVsbg-YE
The goal of our study was to evaluate the impact of the
Nef 17YE sequence variant on SHIVsbg virulence. The nef
mutation was introduced by targeted mutagenesis in
SHIVsbg genome to generate SHIVsbg-YE. We also re-
placed the nef gene of SIVmac239 by the mutated allele to
serve as positive control in in vitro infection of unstimulated
PBMC. SHIVsbg-YE virus was first evaluated by infecting
CEMx174 cells and human or macaque PHA-activated
PBMC in vitro.
SHIVsbg-YE replicated in CEMx174 cells to the same
levels as the parental virus SHIVsbg (data not shown). It
also replicated efficiently as SHIVsbg in activated human
PBMC (Fig. 1A). In contrast to SHIVsbg, which replicated
better on human than rhesus PBMC, SHIVsbg- YE repli-
cated equally well on activated PBMC from both species
(Fig. 1B). In macaque PBMC, SIVmac239-YE replicated
slightly better than the parental virus (data not shown).
SHIVsbg-YE multiplication in unstimulated macaque PBMC
We next evaluated the replication capacity of SHIVsbg-YE
in unstimulated macaque PBMC. Preliminary experiments
demonstrated that the presence of fetal calf serum was
sufficient to activate macaque PBMC and allow replication
of all viruses (data not shown). Moreover, IL-2 addition
results in proliferation of in vivo activated cells and repli-
cation of all viruses. To avoid this activation and prolifer-
ation, PBMC were infected directly after isolation and cul-
tured in serum-free medium AIM grade V in the absence of
IL-2. In these culture conditions, cell viability was some-
what reduced and few fusiform cells were observed in
cultures infected with unmutated RQ viruses or in unin-
fected cultures (Fig. 2A). However, in cultures infected with
YE viruses, cell viability improved and more adherent fusi-
form cells were observed (Figs. 2B and C). Only viruses
bearing the YE mutations were able to replicate in these
conditions (Fig. 1C). SIVmac239-YE generally replicated
faster than SHIVsbg-YE but in some experiments similar
replication kinetics were observed. Progeny viruses were
infectious and replicated efficiently in CEMx174 cells (data
not shown). Therefore, the Nef YE protein allows the rep-
lication of SHIVsbg in unactivated macaque PBMC, a prop-
erty that could enhance its capacity to replicate in vivo.
Infection of rhesus macaques with SHIVsbg-YE
To evaluate the impact of the Nef YE sequence on
SHIVsbg in vivo, we inoculated five Chinese rhesus ma-
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caques with SHIVsbg-YE. Three monkeys were inoculated
intravenously (iv) with 440 TCID50 and two rhesus ma-
caques were inoculated with 7  103 TCID50 by the oral
route. Monkeys were followed by clinical examination,
measurement of the cell-associated viral load, serum RNA
viral load, lymphocyte subsets in peripheral blood, and
HIV-specific humoral immune response.
All five macaques became infected. Clinical examination
revealed persistent lymphadenopathy detectable as soon as
1 week postinoculation for the axillary lymph nodes. Ma-
caques did not develop the severe disease induced by
SIVsmmPBj14 infection but weight loss was observed dur-
ing the first 17 weeks of infection (Fig. 3). At the nadir,
mean weight loss was 9% global weight (range 3.1–14.6%)
and was more pronounced for orally infected monkeys
(11.7%) than for iv inoculated animals (7.2%). Such weight
loss was not observed during primary infection of six rhesus
macaques of Chinese and Indian origin inoculated intrave-
Fig. 2. Adherent cells after infection of unstimulated macaque PBMC. The
adherent cell fraction observed 9 days after infection with SHIVsbg (A),
SHIVsbg-YE (B), and SIVmac239-YE (C) are shown. Mock-infected
cultures and SIVmac239nef stop or SIVmac239nef open infected cultures
were similar to (A).
Fig. 1. Replication of SHIVsbg-YE and its parental viruses in human and
rhesus macaque PBMC. PBMC were infected with cell-free stock of
SHIVsbg, SHIVsbg-YE, SIVmac239, SIVmac- YE, or mock infected.
Virus replication was monitored by measuring RT activity in the culture
supernatant. (A) PHA-activated human PBMC; (B) PHA-activated rhesus
macaque PBMC; (C) unstimulated macaque PBMC.
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nously with the same amount of SHIVsbg (Dunn et al.,
1996). All SHIVsbg-YE infected monkeys had recovered
preinfection weight by 38 weeks postinoculation.
Viral RNA was detected in serum of intravenously in-
fected macaques as early as 4 days postinoculation and later
in orally infected animals. The peak of viremia was reached
after 1.5 or 2 weeks for four of five macaques and was
comprised between 3.9  105 and 2.0  106 RNA copies
per milliliter (Fig. 4). In the case of macaque 93183, the
number of RNA copies remained quasiconstant (4.2 
105–6.6  105 copies per ml) between week 2 and 5
postinfection (Fig. 4B). Viral loads decreased afterward in
all monkeys and after 2 years, viral set point was comprised
between 7.7  102 and 3.6  104 copies per milliliter.
Similarly, PBMC-associated viral load peaked at week 2 or
3 postinfection (50 to 6250 infected cells per 106 PBMC)
and decreased thereafter in all monkeys but less rapidly in
orally infected animals. Low levels of cell-associated virus
were detected for up to 2.4 years (data not shown).
Analysis of lymphocyte subsets in peripheral blood dem-
onstrated that iv inoculated monkeys had a rapid depletion
during the primary infection (2–3 weeks) and for two of
them CD4 lymphocytes increased thereafter to preinfec-
tion level (Fig. 5A). For macaque 93149, the restoration of
CD4 lymphocyte subset was slower and took 1 year to
return to baseline value. The orally inoculated macaques
had a partial depletion of CD4 lymphocytes persisting for
17 weeks, but later they recovered to preinfection values
(Fig. 5B). After 2 years, macaque 93075 developed AIDS
characterized by a CD4 lymphocyte count below 200
cells/l and thrombocytopenia (data not shown).
All monkeys developed HIV-specific antibodies in the
serum (Fig. 6) and seroconversion was concomitant with the
rapid increase of CD20 lymphocyte population in the
peripheral blood (data not shown). Seroconversion occurred
after 2 weeks of infection in iv inoculated macaques and at
3 weeks for orally infected animals. HIV-specific antibody
titers increased sharply for the two groups during the first
month. A continuous increase during the following 2 years
led to sustained levels of HIV-specific antibodies, slightly
higher for the orally infected monkeys.
Growth in unstimulated macaque PBMC and nef
sequences
To evaluate the biological properties of viruses still
present in the infected monkeys, we isolated viruses by
cocultivation of infected macaque PBMC with healthy ma-
caque and tested their capacity to replicate in unstimulated
macaque PBMC. SHIVsbg, SHIVsbg-YE, and SIV-
mac239-YE were used as controls. Whereas virus replica-
tion was observed in cultures infected with YE viruses, no
virus replication was detected in cultures infected with the
viral isolates or the parental SHIVsbg (Fig. 7).
To evaluate if nef gene alterations could be responsible
for the failure to replicate in nonstimulated PBMC, nef
Fig. 4. Viral RNA copies in the serum of SHIVsbg-YE-infected macaques.
The number of RNA copies, expressed per ml of serum, was determined by
real-time RT-PCR for (A) iv infected monkeys (93071, 93093, and 93149)
and (B) orally infected macaques (93075 and 93183). Black arrow indi-
cates the time postinfection at which nadir of body weight loss was
observed.
Fig. 3. Evolution of macaques weight. Macaques were weighed after
anesthesia at each blood collection. The weight is expressed as the per-
centage of body weight increase compare to the day of virus inoculation.
Macaque 93071 was euthanized 94 weeks p.i.
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genes were amplified and sequenced (Fig. 8). Extensive
alterations were observed in the nef genes of viruses isolated
from two iv inoculated macaque viruses. Although the YE
site was retained in most of these viruses, 33-bp in-frame
deletions were detected in multiple isolates from macaques
93071 and 93149. The deletions observed in viruses from
these two monkeys differed from each other by a two codon
shift but both impaired the TyrX2Leu site located seven
amino acids downstream of the YE site. In contrast, no
deletion was observed in the nef gene of viral isolates
obtained from orally infected macaques. However codon 17
reverted back from tyrosine to arginine, inactivating also the
ITAM motif.
Retrospectively, we analyzed nef genes of viruses iso-
lated at earlier time points to determine if nef alteration
could be implicated in the clinical improvement. The nef
deletion was detected as soon as 8 weeks postinoculation in
viruses isolated from macaque 93071 but full-length nef
(YE) was still present (representing approximately 20%). At
12 weeks, leucine 31 was substituted by a proline and after
17 weeks postinoculation only deleted nef genes were re-
vealed in isolates originating from PBMC or different
lymph nodes collected at time of necropsy. For macaque
Fig. 5. Variation of CD4 lymphocytes in rhesus macaques infected with
SHIVsbg-YE. Absolute number of CD4 lymphocytes are represented for
(A) iv infected monkeys (93071, 93093, and 93149) and (B) orally infected
macaques (93075 and 93183). Black arrow indicates the time postinfection
at which nadir of body weight loss was observed.
Fig. 6. HIV-specific antibody titers in SHIVsbg-YE-infected macaques.
Antibody response was determined on serum of the infected animals with
a commercial HIV ELISA kit (Murex HIV 1.2.O). Antibody titers are the
reciprocals of the highest serum dilution giving an optical density of at
least 0.1 above the cutoff value. Cutoff value (1) is depicted by a line and
antibody titer below are considered as negative. Orally infected macaques
(93075 and 93183) are depicted by open symbols, iv inoculated monkeys
(93071, 93093, and 93149) are depicted by filled symbols. Black arrow
indicates the time postinfection at which nadir of body weight loss was
observed.
Fig. 7. In vitro phenotype in unstimulated macaque PBMC of viral
isolates recovered from SHIVsbg-YE-infected monkeys. Replication of
viruses isolated from macaque 93071 (92 weeks p.i.), 93149 (92 weeks
p.i.), 93075 (120 weeks p.i.), and 93183 (105 weeks p.i.) was evaluated
in unstimulated macaque PBMC as described under Materials and
methods. Infection with SHIVsbg-YE and SIVmac239- YE served as
positive controls and cultures uninfected or infected with SHIVsbg as
negative controls.
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Fig. 8. Sequence of the N-terminal extremity of Nef protein from virus isolated from SHIVsbg-YE infected macaques. Virus were isolated from several
tissues: PBMC, tonsil (TON), mesentheric lymph nodes (MLN), inguinal lymph nodes (ILN), axillary lymph nodes (ALN), and colonic lymph nodes (CLN).
The nef gene of virus isolates was sequenced and amino acid sequences of the N-terminal extremity are depicted. Dashes indicate amino acids identical to
SHIVsbg Nef protein. Dots indicate deleted amino acids. An asterisk marks isolate containing parental and deleted genes. Mutations are indicated in bold
capitals for nonsynonymous mutations and in lowercase letters for synonymous mutations. Localization of the tyrosine potentially involved in TyrXXLeu
motifs is highlight by a box. The two consensus TyrXXLeu motifs, constituting an ITAM domain, are indicated as gray boxes, whereas mutated sequences
are in white boxes. Sequences of seric viruses collected at different time points after infection were determined by direct RT-PCR sequencing and are
indicated in italic. For some samples, two populations of viruses were detected concomitantly; both sequences are indicated. Note that the nadir of body
weight loss was observed 17 weeks postinfection.
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93149, the deletion was established 31 weeks postinocula-
tion. It was preceded by the mutation of leucine 31 in
phenylalanine as early as 5 weeks postinoculation. For the
third animal (93093) the same punctual mutation of leucine
31 was detected after 31 weeks postinoculation, suggesting
that this mutagenesis event may be necessary for the fol-
lowing deletion. In the orally infected group, viruses iso-
lated from both monkeys carried an altered ITAM motif
from 17 weeks postinoculation. The reversion of tyrosine 17
(TAC) to arginine (CGC) uses an intermediate transition in
histidine (CAC). Therefore all viruses carried a mutated
ITAM motif. As SIVsmmPBJ14 replication capacity is as-
sociated with the presence in Nef protein of two TyrX2Leu
motifs forming an ITAM motif, the two types of Nef alter-
ations could be responsible for the absence of replication of
the viral isolates in unstimulated macaque PBMC. However
the Nef protein of all mutated viruses had maintained a
motif of two tyrosines spaced by 11 amino acids, using in
the case of deleted nef genes either Tyr 17 and 39 (93071)
or Tyr 17 and 28 (93149). For orally infected macaques, Tyr
28 and 39 were maintained after Tyr 17 reverted back to
Arg (Fig. 8).
Sequence determination on genome of viruses collected
in the serums at different times postinfection indicates that
mutations detected in viruses produced in vitro by activated
PBMC are also present in viruses produced in vivo.
Discussion
In this study we describe the effect of 17YE Nef protein
mutation on multiplication of SHIVsbg in vitro and its
virulence in Chinese rhesus macaques. Introduction of the
17YE mutation allowed SHIVsbg to replicate in unstimu-
lated rhesus macaque PBMC. This observation is consistent
with previously published characteristics of SIVmac239-YE
and the acute pathogenic SIVsmmPBj14, although these
viruses use a different coreceptor in vitro (Du et al., 1995;
Schwiebert et al., 1997). Ability to replicate in resting
PBMC was also observed with a chimeric virus (SHIVPPcP-
Bjnef) bearing the nef/LTR region from SIVsmmPBj14, but
in this case, coreceptor usage was not established (its enve-
lope gene was cloned from a virus stock of sequentially
passaged SHIV-4 and compared to this, later, predicted
amino acids substitutions in the V3 loop were reported,
Stephens et al., 1998). We hypothesized that the capacity to
replicate in nonstimulated PBMC would allow SHIVsbg to
infect productively a larger number of cells in vivo and
therefore confer an increased virulence. However, after in-
travenous and oral inoculation of juvenile rhesus macaques,
no acute phenotype was observed in the infected animals.
SHIVsbg-YE replicated efficiently during primary infection
but was not highly pathogenic.
Macaques species, route of inoculation, and viral dose
could be factors involved in this weak virulence (Shibata et
al., 1997). Indeed after iv inoculation with SIVsmmPBj14,
only 30– 50% of rhesus macaques suffered from severe
symptoms and died, in contrast to a 100% mortality ob-
served in pig-tailed macaques (Lewis et al., 1992). More-
over the route of inoculation can play an important role. For
example, pig-tailed macaques infected by rectal or vaginal
exposure to SIVsmmPBj14 generally developed an acute
disease syndrome (diarrhea, anorexia, depression, and rash)
but less than 50% died (Fultz et al., 1995). Previous study
has shown that day of onset of disease and death was a
function of the inoculated dose (Fultz and Zack, 1994).
Similarly, Endo and collaborators reported recently that
rhesus monkey iv inoculated with 650 TCID50 of patho-
genic SHIVDH12R or more suffered irreversible CD4 loss
in contrast to animals inoculated with lower doses (Endo et
al., 2000). Coreceptor utilization may also play a role as
animals infected with the R5 and X4 SHIV, expressing in
these cases the SIVmac239nef gene, have distinct patho-
genic outcomes despite comparable levels of viral replica-
tion (Harouse et al., 1999). Clinical examination of
SHIVsbg-YE-infected macaques revealed only a persistent
lymphadenopathy and a weight loss up to 14.6% at the nadir
(17 weeks postinoculation), which was not observed in the
course of SHIVsbg infection. It could be associated with
viral replication in lymphoid tissues such as lymph node and
gut-associated lymphoid tissues (GALT). Indeed, GALT is
a major site for lentiviral replication, especially for
SIVsmmPBj14 and SIVmac239-YE that induce hyperplasia
of Peyer’s patches (Fultz and Zack, 1994; Sasseville et al.,
1996; Veazey et al., 1998; Veazey and Lackner, 1998). The
extremely intense lymphoproliferation observed in GALT
of SIVsmmPBj14-infected monkeys was associated with
the expression on infected cells of E7 integrin (CD103),
an adhesion molecule involved in GALT homing of lym-
phocytes (Gummuluru et al., 1996). Moreover, acute repli-
cation was associated with elevated levels of inflammatory
cytokines (IL-6 and TNF), which could be responsible for
maladsorption and weight loss observed during acute infec-
tion.
Depletion of the CD4 lymphocytes was more pro-
longed in orally exposed monkeys than in two of the three
iv infected macaques. For the latter monkeys (93071,
93093), serum viral load was also 10 times lower from 5 to
12 weeks p.i. After 17 weeks of infection, clinical param-
eters started to return to their preinfection level. Concomi-
tantly CD4 lymphocytes increased in the blood and cell-
associated viral load decreased, demonstrating that a better
control of viral multiplication was achieved by the immune
system of the infected macaques. The infection was persis-
tent as, after 2 years postinoculation, viral set point was
comprised between 7.7  102 and 2.4  104 viral RNA
copies per milliliter, even when virus could not be isolated
from 106 PBMC. Comparison with historical SHIVsbg in-
fection can be made as animals inoculated intravenously
received the same dose of virus (Dunn et al., 1996). In the
case of SHIVsbg infection, following the peak of viremia
(mean value 0.9  106 RNA copies/ml serum) viral set
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point measured was between 102 and 103 RNA copies/ml
serum (L. Gloeckler, unpublished data).
To evaluate virus variation after 2 years of replication in
vivo, analyses were done on isolated virus rather than di-
rectly amplified proviral DNA. Indeed studies have shown
that during the asymptomatic phase of HIV infection, most
of the viral sequences are found in quiescent CD4 cells, in
an unintegrated form that does not represent replication-
competent virus (Chun et al., 1997). Moreover defective
proviruses accumulated in asymptomatic patients (Sanchez
et al, 1997). We could recover viruses from PBMC as well
as lymphoid organs, confirming that replication-competent
viruses were indeed present in the infected animals after 2
years of infection. Phenotypic tests and envelope gene se-
quencing demonstrated that these viral isolates had not
changed their CXCR4 usage (data not shown), indicating
that oral infection can take place with an X4 virus.
The viruses isolated 2 years postinoculation no longer
replicated in unstimulated macaques PBMC. Sequence
analysis of nef genes demonstrated that the ITAM motif was
inactivated by either a point mutation of tyrosine 17 or a
33-bp downstream deletion, altering the second TyrX2Leu
site. These modifications were detected not only in the
genome of viruses produced in vitro by activated PBMC but
also in the genome of viruses present in the plasma. The two
different mechanisms of inactivation were observed de-
pending on the route of inoculation. In pig-tailed macaques
persistently infected by SIVsmmPBj14 after mucosal expo-
sure, previous sequences analyses of nef gene have also
shown that the ITAM motif was inactivated by point mu-
tations of the first or the second tyrosine (Schwiebert et al.,
1997). We have shown that ITAM alteration correlates with
clinical improvement of the infected monkeys.
Why is this motif inactivated? On one hand, the ITAM
motif in Nef may confer a replication advantage to the virus
in persistently infected animals. SIV possessing the Nef YE
allele were isolated in several studies in animals enduring an
increase of viral replication and a progression to death
(Dewhurst et al., 1990; Kirschhoff et al., 1999). It would
contribute to cell activation after phosphorylation of the two
tyrosines by Lck and interaction with ZAP-70, a T cell
specific tyrosine kinase, when lymphocytes are in an anergic
state during long-term infection (Luo and Peterlin, 1997).
Presence of macrophages is also necessary to trigger lym-
phoproliferation and costimulatory molecules such as B7-1,
B7-2, and CD40 are involved in the process (Du et al., 1995;
Whetter et al., 1998). On the other hand the ITAM motif
appeared to be counterselected in animals that did not suc-
cumb to the acute infection after SIVsmmPBj14 mucosal
exposure or in our case iv and oral SHIVsbg-YE infections.
These contrasting observations indicate that after primary
infection and the development of an immune response,
presence of an ITAM motif could be detrimental for viral
replication as recovered viruses bear mutations altering this
motif. Macaques infected with SIVsmmPBj14 generally
died between 6 and 14 days postinoculation when immune
responses were minimal or undetectable (Fultz and Zack,
1994; Lewis et al., 1992). This strong selection may be due
to an interference of ITAM with other well-conserved func-
tions of Nef protein important for evading immune control.
The well-conserved tyrosines in position 28 and 39 of SIV
Nef protein have been shown to be involved in the interac-
tion and cellular colocalization of Nef with the 2 subunit
of AP-2 (Lock et al., 1999; Piguet et al., 1998). Moreover
studies indicate that these tyrosine-based motifs play a role
in CD4 down regulation, which is best revealed in the
context of composite mutations with the leucine-based mo-
tif at position 194–195 (Bresnahan et al., 1999). The ITAM
motif partially overlaps the tyrosine domains and may in-
terfere, by steric obstruction or tyrosine phosphorylation,
with functions associated with these two tyrosines in vivo.
In persistently infected animals with a strong immune re-
sponse, the function associated with these tyrosines could be
more beneficial to virus replication than cell activation that
is generally high. At later times, in animals having a weaker
immune system and anergic lymphocytes, Nef protein with
an ITAM motif could stimulate viral replication, thereby
accelerating progression to death. Further analyses will be
needed to clarify the precise function of Nef–2 interaction
in infected animals.
Materials and methods
Construction of SHIVsbg-YE and SIVmac239-YE
Classical techniques of molecular biology used were
similar to those described by Sambook et al (1989). The
17th and 18th codons of SIVmac239 nef gene were mutated
from CGACAG to TACGAG by targeted mutagenesis using
the Scultor in vitro mutagenesis system (Amersham).
Briefly, the pTG5043 plasmid, encoding the 3 half genome
of SHIVsbg, was digested with SmaI and PvuII. The 1311-
bp fragment encompassing the nef gene was cloned into the
lacZ gene of the M13TG131 phage vector linearized with
SmaI and dephosphorylated with calf intestine phosphatase.
XL-1 Blue Escherichia coli were transformed with the li-
gation products and white plaques were picked.
Double-stranded DNA was prepared and screened for the
insertion by BamHI and HindIII restriction analysis. Single-
stranded DNA was prepared and used with a phosphorylated
primer NEFOMYE (5- CGCCCGCAAGAGTCTCTCGTA-
CAGATCTCCAGACGG-3) in a targeted mutagenesis reac-
tion according to the manufacturer’s instructions. XL-1
Blue E. coli were transformed with the mutagenesis reaction
product and phages were screened for the presence of the
mutations by sequencing single-stranded DNA using the
Sequenase kit (Amersham). The 201-bp mutated nef frag-
ment was purified after digestion of double-stranded DNA
with RsrII and NcoI and cloned into pTG5043 digested by
RsrII and NcoI and dephosphorylated. The nef gene in the
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resulting recombinant plasmid p3SHIV-YE was sequenced
using the Sequenase kit.
The mutagenized nef gene was also introduced into the
SIVmac239 genome. The 1694-bp BglII-EcoRI fragment of
p3SHIV-YE, encompassing the mutated nef gene and the
LTR, was ligated to the p239SpE3 plasmid, encoding the
3 half genome of SIVmac239, previously digested by BglII
and EcoRI. The resulting plasmid p3SIV-YE was verified
by restriction analysis and nef gene sequencing using Se-
quenase kit.
Cells and viruses
CEMx174, a CD4 T/B cell hybrid cell line, was main-
tained at 37°C and 5% CO2 in RPMI complete medium
[RPMI 1640 (Gibco) supplemented with 10% decomple-
mented fetal calf serum (FCS), 2 mM L-alanyl-L-glutamine
(Glutamax I, Gibco), 100 g of streptomycin per ml, and
100 IU of penicillin per ml].
Human and macaque PBMC were isolated from whole
blood of healthy donors by density gradient centrifugation
on a Ficoll–Hypaque cushion (Eurobio, France), washed
with phosphate-buffered saline (PBS), and counted. They
were stimulated for 3 days with 4 g phytohemagglutinin A
(PHA, Sigma) per milliliter in RPMI complete medium
supplemented with 20 IU interleukin-2 (IL-2) per milliliter.
Unstimulated macaque PBMC were cultured in AIM grade
V medium (Gibco) with 2 mM L-alanyl-L- glutamine with-
out any other supplementation.
SHIVsbg, SHIVsbg-YE, SIVmac239nefstop, and SIV-
mac239-YE were produced in CEMx174 cells. Viral ge-
nomes were reconstructed in vitro by ligation of SphI lin-
earized plasmids encoding the 5 and 3 half genomes:
pTG4036 and pTG5043 for SHIVsbg (Dunn et al., 1996),
pTG4036 and p3SHIV-YE for SHIVsbg-YE, p239SpSp5,
and p239SpE3 (kindly provided by Dr. Desrosiers through
the NIH AIDS reagent program) for SIVmac239nef stop
(Naidu et al., 1988; Regier and Desrosiers, 1990), and
p239SpSp5 and p3SIV-YE for SIVmac239-YE. Ten mil-
lion CEMx174 cells were electroporated with 10 g of
ligated DNA in 800 l RPMI complete medium under 1500
F and 280 V in an Easyject Plus apparatus (Eurogentech,
Seraing, Belgium) and then cultured at 1 million cells per
milliliter in RPMI complete medium. Cultures were ob-
served for cytopathic effects and virus production was eval-
uated by measuring reverse transcriptase (RT) activity in
culture supernatant (Moog et al., 1994). Once increasing RT
activity was detected, 24 h supernatants were harvested for
virus stocks and filtered through 0.45-m filters.
For macaque inoculation, we used a SHIVsbg-YE stock
grown in macaque PBMC, having a titer of 2330 TCID50
per milliliter on CEMx174 cells and 39 ng of p27 antigen
per milliliter as determined by ELISA (Innotest HIV antigen
mAb screening, Innogenetics, Zwijndrecht, Belgium).
Infection of cell line and PBMC
Five million CEMx174 cells were infected with identical
quantities of viruses determined on the basis of RT activity
(105 cpm). Cells were incubated with the virus for 1 h at
37°C and then washed with PBS and cultured at 1 million
cells per milliliter in RPMI complete medium. Culture me-
dium was replaced twice weekly and cell concentrations
were adjusted at these occasions.
A similar protocol was used to infect activated human
and rhesus macaque PBMC cultured in RPMI complete
medium supplemented with 20 IU IL-2 per milliliter.
Unstimulated macaque PBMC were infected immedi-
ately following isolation with the same protocol used for
stimulated PBMC. After 1-h incubation at 37°C, cells were
washed with PBS and cultured at 1–2 million cells per
milliliter in AIM grade V medium with 2 mM L- alanyl-L-
glutamine. Half of the culture medium was replaced with
fresh medium twice weekly without perturbing the cells.
Animals
Chinese rhesus macaques (Macaca mulatta), 3- to
4-year-old juvenile monkeys, were maintained according to
the conditions stipulated in the European guidelines. Ani-
mals were sedated with ketamine HCl (10 mg/kg; Imalgene,
Me´rieux) for clinical examination, blood sampling, lymph
node biopsies, and virus inoculation. Blood samples were
collected by saphenous venipuncture. Three monkeys
(93071, 93093, and 93149) were inoculated in the saphe-
nous vein with 440 TCID50 of the cell-free SHIVsbg-YE
stock produced in macaque PBMC. After examination of
the oral cavity to verify the absence of lesions and inflam-
mation, two other rhesus monkeys (93075 and 93183) were
inoculated orally with 7.0  103 TCID50 in 3 ml. During the
primary infection, clinical examination of monkeys was
performed twice weekly and less frequently thereafter.
Immunophenotyping
Lymphocyte subsets were evaluated by flow cytometry.
Whole-blood samples were stained with either anti-CD4 PE
(OKT4, Ortho, Roissy, France) or anti-CD8 FITC (Leu2a,
Becton–Dickinson, Le Pont de Claix, France) monoclonal
antibodies or with anti-CD20 FITC monoclonal antibody
(B9H9, Immunotech, Marseille, France). Red blood cells
were lysed with the Facs lysing solution (Becton–Dickin-
son) according to the manufacturer’s instructions. Cells
were washed twice in FACSflow and resuspended in 1.5%
formaldehyde in PBS. Samples were analyzed on a FACS-
can flow cytometer (Becton–Dickinson) and data were col-
lected in list mode using the CellQuest software with at least
3000 events in a lymphocyte gate defined by the FSC-SSC
parameters.
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Serology
HIV-specific antibody titers in the sera of the infected
macaque were quantified with a commercial HIV ELISA kit
(Murex HIV-1.2.O, Murex Diagnostics S.A., Chatillon,
France) following the manufacturer’s instructions. Anti-
body titers were determined as the reciprocal of the highest
dilution giving an optical density of a least 0.1 above the
cutoff values.
Determination of cell-associated viral load
Macaque PBMC were purified from heparinized blood
by density gradient centrifugation on a Ficoll–Hypaque
cushion (Eurobio). Quantitative determination of the cell-
associated viral load was performed by cocultivating 106, 5
 105, and five-fold serial dilutions of the PBMC with 1.5
 105 CEM  174 cells in 24-well plates. The cocultures
were maintained for 4 weeks and treated twice weekly, once
to change the culture medium (RPMI complete medium)
and once to divide the cells. The RT activity in culture
supernatant was determined at each time and its increase
was taken as evidence of viral replication. The cell-associ-
ated viral load was expressed as the number of infected cells
per 106 cells. After 12 weeks of infection, cocultures of
CD8 depleted PBMC were also performed in parallel.
Quantification of viral RNA in serum
Viral RNA was extracted from 250 l of macaque se-
rums collected at different times postinfection as described
in the paragraph RT-PCR amplification and concentrated in
25 l of water. Determination of the number of viral RNA
was made in duplicate by real-time RT-PCR (5 l of RNA
per assay), with the TaqMan EZ RT-PCR kit (PE Applied
Biosystems), according to the protocol described (Hof-
mann-Lehmann et al., 2000) using an i-cycler (Bio-Rad).
Under these conditions, a concentration of 400 copies of
viral RNA per milliliter of serum was measurable.
Virus isolation from macaque PBMC and lymphoid
organs
PBMC were purified from infected macaque blood using
Ficoll–Hypaque cushion and CD8 cells were removed
using magnetic beads coupled to antihuman CD8 monoclo-
nal antibody (Dynal). Two million CD8-depleted PBMC
were cultivated in complete medium [RPMI 1640  10%
FBS  20 IU IL-2 per ml] supplemented with 4 g PHA
per milliliter. After 3 days, the cells were washed with PBS
and cocultivated in complete medium with 2 million CD8-
depleted, PHA-activated PBMC from a healthy macaque.
Virus replication was checked twice weekly by quantifying
RT activity in culture supernatant or by quantifying p27
antigen with a p24 ELISA (Innotest HIV antigen mAb
screening; Innogenetics).
For virus isolation from the organ cells, lymph node
samples were dissociated with scissors and vigorous pipet-
ting followed by filtration through a 70-m nylon cell
strainer (Becton–Dickinson) to obtain a single-cell suspen-
sion. Cells were depleted of CD8 cells and then cultivated
in the same conditions used for PBMC.
Determination of co-receptor usage
Evaluation of chemokine receptor usage for cell entry
was performed using the GHOST cell lines, obtained from
the AIDS Research Project (Program EVA centralized Fa-
cility–NIBSC, Potters Bar, UK). GHOST cells are derived
from the human osteoscarcoma (HOS) cell line that ex-
presses CD4 alone or with one of the chemokine receptors
(CCR5, CXCR4, Bob, Bonzo) known to be used as core-
ceptor by primate lentiviruses. These cells also carry the
gene for green fluorescent protein (GFP) under the control
of the HIV-2 promoter, which is trans-activated by Tat
following virus entry. Infected cells expressing GFP were
enumerated by flow cytometry. GHOST cells were culti-
vated in Dulbecco’s modified Eagle’s medium (DMEM)
with 10% FCS, 500 g Geneticin sulfate (Gibco-BRL) per
milliliters and 100 g hygromycin (Sigma) per milliliter.
For cell lines expressing one of the chemokine receptors,
culture medium was supplemented with 1 g puromycin per
milliliter. Cells were distributed in 12-well plates at 105
cells per well and cultured overnight. They were infected
the following day for 1 h with SHIVsbg, SHIVsbg-YE,
SIVmac239-YE, HIV-1 B08, and viruses isolated from
SHIVsbg- YE-infected macaques. After 2 days of culture in
DMEM  10% FCS, cells were detached from the well by
incubation with trypsin–EDTA, washed in PBS, resus-
pended in 500 l 1.5% formaldehyde in PBS, and analyzed
for GFP expression on a FACScan flow cytometer (Becton–
Dickinson).
RT-PCR amplification
The sequences encoding Nef protein were amplified by
RT-PCR from genomic RNA of SHIVsbg, SHIVsbg-YE, or
viral isolates. Viral RNA was extracted by mixing 250 l of
serum with 750 l Tri Reagent (Molecular Research Center
Inc., Cincinati, OH). After 5 min, 200 l of trichloroethane
was added and 5 min later the aqueous phase was recovered
after centrifugation. The viral RNA was isopropanol-pre-
cipitated, pelleted by centrifugation, and washed with 70%
ethanol. The RNA pellet was solubilized in 25 l water.
Reverse transcription was carried out in 20 l containing 35
pmol reverse primer NEF2 (5- AGAACCTCCCAGGGCT-
CAATCT-3), 2 l of 10 PCR Buffer II (Perkin–Elmer
Applied Biosystem Division, Foster City, CA), 5 mM
MgCl2, 1 mM dNTP, 20 U RNasin (Pharmacia Biotech,
Uppsala, Sweden), and 50 U MuLV reverse transcriptase
(Perkin–Elmer) and incubated for 30 min at 42°C.
The PCR amplifications were carried out in a DNA
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thermal cycler (Perkin–Elmer) in 100 l reaction volume
consisting of 20 l reverse-transcribed RNA, 75 mM Tris–
HCl pH 9.0, 20 mM (NH4)2SO4, 0.01% (w/v) Tween 20, 2.5
mM MgCl2, 200 M dNTP, 35 pmol OPEL sense primer
(5-CTTGTAGAGCTATTCGCCACATAC-3), and 1.5 U
of Gold Star DNA polymerase (Eurogentec). The reverse
primer, already present in the sample, was not added again
in the PCR mix. The amplification program comprised 5
min denaturation at 94°C, 30 cycles of 1 min at 94°C, 1 min
at 60°C, and 1 min at 72°C, and finally 8 min at 72°C.
The PCR products were separated on a 2% agarose gel
and purified with the Wizard PCR preps DNA purification
System (Promega Corp., Madison, WI) according to the
manufacturer’s specifications. The sequencing reactions
were performed directly on the PCR products by Genome
Express Co. (Grenoble, France) using the fluorescent
dideoxynucleotide terminator protocol and analyzed on an
automated 377 ABI Prism sequencer.
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